Atossa Therapeutics Appoints Janet R. Rea to Accelerate R&D for Breast Cancer Drug (Z)-Endoxifen
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a pioneering biopharmaceutical firm dedicated to innovative treatments for breast cancer, has made a significant leadership change by appointing Janet R. Rea, MSPH, as the Senior Vice President of Research and Development. This move is seen as a strategic effort to advance the regulatory process for (Z)-endoxifen, a compound that has drawn considerable attention due to its potential in reshaping treatment protocols for breast cancer.
Janet R. Rea is no stranger to the biopharmaceutical world, boasting over twenty years of experience in strategic research and clinical development, particularly in navigating the complex landscape of regulatory approvals. As she takes the helm of late-stage (Z)-endoxifen programs, Ms. Rea aims to focus on immediate priorities such as upcoming submissions to the FDA, stakeholder interactions, and charting a clear path toward commercialization.
Prior to her appointment at Atossa, Ms. Rea served as a consultant for various biopharmaceutical companies, and held crucial leadership roles at prominent firms like AVM Biotechnology, where she was the Chief Operating Officer, as well as tenure at Protein Sciences (now part of GlaxoSmithKline). During her illustrious career, she has played an instrumental part in securing regulatory approval for groundbreaking therapies, including the egg-free influenza vaccine, FluBlok®, underscoring her capability to drive projects from conception through to market.
The history between Ms. Rea and Atossa Therapeutics is noteworthy. She previously held the position of Senior Vice President for Regulatory and Clinical Affairs at Atossa, during which she secured regulatory endorsements for (Z)-endoxifen and effectively managed clinical studies across several countries, including the U.S., Australia, and Sweden. These studies are foundational to Atossa's breast cancer treatment initiatives, and her return is seen as a catalyst for propelling the company’s therapeutic pipeline forward.
Dr. Steven Quay, CEO of Atossa Therapeutics, expressed enthusiasm about Ms. Rea's return, stating, "Janet's extensive experience in navigating regulatory and clinical landscapes is crucial for our mission to bring transformative treatments to market. Her hands-on approach and proven success in advancing similar programs match precisely with our ambitious goals for (Z)-endoxifen."
As Atossa Therapeutics stands at what is termed an ‘exciting inflection point’, it opens a new chapter in its journey. The strategic focus is clear: to expedite the introduction of (Z)-endoxifen into the market, addressing the pressing clinical needs associated with breast cancer treatment. Janet R. Rea shares this vision and remarked, "I am thrilled to rejoin the team and advance promising (Z)-endoxifen therapies to market."
Atossa’s lead product candidate, (Z)-endoxifen, is engineered to be a powerful Selective Estrogen Receptor Modulator (SERM) designed for application across the spectrum of breast cancer, from risk mitigation to therapeutic interventions in a variety of clinical settings. The company's commitments are not just toward patient health but also reflect a clear aim for sustainable growth in shareholder value.
As the biopharmaceutical landscape is continually reshaped by innovation and regulatory developments, Atossa Therapeutics is poised to lead the charge in breast cancer solutions, under the astute guidance of Janet R. Rea. The industry eagerly anticipates the outcomes of her strategic initiatives, which may well redefine management protocols and enhance patient outcomes in breast cancer therapy.
Janet R. Rea is no stranger to the biopharmaceutical world, boasting over twenty years of experience in strategic research and clinical development, particularly in navigating the complex landscape of regulatory approvals. As she takes the helm of late-stage (Z)-endoxifen programs, Ms. Rea aims to focus on immediate priorities such as upcoming submissions to the FDA, stakeholder interactions, and charting a clear path toward commercialization.
Prior to her appointment at Atossa, Ms. Rea served as a consultant for various biopharmaceutical companies, and held crucial leadership roles at prominent firms like AVM Biotechnology, where she was the Chief Operating Officer, as well as tenure at Protein Sciences (now part of GlaxoSmithKline). During her illustrious career, she has played an instrumental part in securing regulatory approval for groundbreaking therapies, including the egg-free influenza vaccine, FluBlok®, underscoring her capability to drive projects from conception through to market.
The history between Ms. Rea and Atossa Therapeutics is noteworthy. She previously held the position of Senior Vice President for Regulatory and Clinical Affairs at Atossa, during which she secured regulatory endorsements for (Z)-endoxifen and effectively managed clinical studies across several countries, including the U.S., Australia, and Sweden. These studies are foundational to Atossa's breast cancer treatment initiatives, and her return is seen as a catalyst for propelling the company’s therapeutic pipeline forward.
Dr. Steven Quay, CEO of Atossa Therapeutics, expressed enthusiasm about Ms. Rea's return, stating, "Janet's extensive experience in navigating regulatory and clinical landscapes is crucial for our mission to bring transformative treatments to market. Her hands-on approach and proven success in advancing similar programs match precisely with our ambitious goals for (Z)-endoxifen."
As Atossa Therapeutics stands at what is termed an ‘exciting inflection point’, it opens a new chapter in its journey. The strategic focus is clear: to expedite the introduction of (Z)-endoxifen into the market, addressing the pressing clinical needs associated with breast cancer treatment. Janet R. Rea shares this vision and remarked, "I am thrilled to rejoin the team and advance promising (Z)-endoxifen therapies to market."
Atossa’s lead product candidate, (Z)-endoxifen, is engineered to be a powerful Selective Estrogen Receptor Modulator (SERM) designed for application across the spectrum of breast cancer, from risk mitigation to therapeutic interventions in a variety of clinical settings. The company's commitments are not just toward patient health but also reflect a clear aim for sustainable growth in shareholder value.
As the biopharmaceutical landscape is continually reshaped by innovation and regulatory developments, Atossa Therapeutics is poised to lead the charge in breast cancer solutions, under the astute guidance of Janet R. Rea. The industry eagerly anticipates the outcomes of her strategic initiatives, which may well redefine management protocols and enhance patient outcomes in breast cancer therapy.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.